Global symptoms of dyspepsia · patients with functional dyspepsia
Proton pump inhibitors (PPI) probably leads to lower global symptoms of dyspepsia (> 2 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life or psychological well‐being (higher = higher quality of life or psychological well‐being): end‐of‐intervention · patients with functional dyspepsia
1 finding from 1 review
Adverse events · patients with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in global symptoms of dyspepsia compared with H2 receptor antagonists (H2RA) (low certainty).
1 finding from 1 review
Quality of life · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with H2 receptor antagonists (H2RA) (moderate certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors (PPI) may leads to lower global symptoms of dyspepsia compared with prokinetics (low certainty).
1 finding from 1 review
Quality of life Korean version of the dyspepsia related Nepean Dyspepsia Index (NDI) from: 0 to 99 · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with prokinetics (moderate certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors plus prokinetics showed no clear difference in global symptoms of dyspepsia compared with prokinetics alone (moderate certainty).
1 finding from 1 review
Quality of life Korean version of the dyspepsia related Nepean Dyspepsia Index (0 to 99) and Functional Digestive Disorders Quality of Life questionnaire (FDDQL) scale · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors plus prokinetics probably leads to lower adverse events compared with prokinetics alone (moderate certainty).
1 finding from 1 review
Clinically important upper GI bleeding · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in clinically important upper GI bleeding compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PPI versus placebo Symptomatic outcome measures · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention leads to lower PPI versus placebo Symptomatic outcome measures (high certainty).
1 finding from 1 review
Intervention not reported
PPI versus H2RA · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower PPI versus H2RA (moderate certainty).
1 finding from 1 review